Patrick Joseph Igoe
Life Sciences Patent Attorney, Independent IP Litigation Consultant
Member of the Law Council
Council Member Biography
Patrick Joseph Igoe is a consultant and registered patent attorney in New York. His focus is patent issues throughout Life Sciences - for example, diagnostic/therapeutic assays; medical devices/imaging technologies; Rx antibiotics, biologics, drugs, and vaccines; and OTC medicines. His expertise includes active ongoing evaluations of now-current patent and/or FDA litigations. Mr. Igoe directly handles both typical patent areas and IP deals. He has completed numerous patent filings and deals, directed licensing campaigns, and drafted commercial/IP contracts. His expertise includes subjects such as antidepressants; small molecule organic chemistry; catalytic antibody prodrugs; drug-eluting stents; crop protection pesticides; cancer assays; animal vaccines; birth control implants; drug-eluting polymers; and stereochemistry. Mr. Igoe has served as in-house counsel at Bayer Diagnostics, Wyeth, and Igen. He holds a JD from Albany Law School and a BS in Chemistry/Math from Union College. (This is me - Update Profile)
Employment History
- 2003 - present
- Life Sciences Patent Attorney, Independent IP Litigation Consultant
- 2000 - 2003
- In-House Legal Counsel, Bayer Diagnostics (now Siemens Medical Solutions Diagnostics [NYSE:SI])
- 1997 - 2000
- In-House Legal Counsel, American Home Products (now Wyeth [NYSE:WYE])
- 1993 - 1997
- In-House Legal Counsel, IGEN (now Roche)
- 1992 - 1993
- Assistant Patent Examiner/GS13 level, United States Patent And Trademark Office/Group Art Unit 1102/electrochemistry/classes 204 and 205
GLG NewsSM Analyses by Patrick Joseph Igoe(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
April 2, 2009
Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
Teva Introduces First Generic Adderall XR® Capsules in the United States | www.tevapharm.com
(1) As stated in the 02 Apr 2009 Press Release, Teva Pharmaceutical Industries Ltd. (NasdaqGS:TEVA) has launched its generic versions corresponding to the FDA-approved Orange Book Reference Listed Drug (RLD) medical products of ADDERALL XR Capsules (mixed salts of a single-entity amphetamine product;...
-
OXYCONTIN Update: Ratiopharm And Sandoz Infringe 2 European Patents Controlled By Napp And Purdue
April 2, 2009
Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
OXYCONTIN Update: England Patent Infringement Victory {Napp Pharmaceutical Holdings Ltd v Ratiopharm GmbH [2009] EWCA Civ 252 (01 April 2009)} | www.bailii.org
(1) In this article, the London 01 Apr 2009 html version of judgment of the England and Wales Court of Appeal (Civil Division), a recent appellate court decision provides Napp and Purdue, in protecting OXYCONTIN, with a definitive patent infringement victory over both Ratiopharm GmbH andSandoz...
-
March 30, 2009
Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
Teva (NasdaqGS:TEVA) Announces FDA Response to Citizen Petition (Re COPAXONE ANDA) | www.tevapharm.com
As stated in the 25 Mar 2009 press release by Teva (NasdaqGS:TEVA), the FDA recently denied Teva's Citizen Petition (CP) which was previously filed 26 Sep 2008. Teva is now fully-engaged in its dual efforts to protect its American COPAXONE sales. These dual efforts are (1) at the FDA: through...
-
March 25, 2009
Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc. | www.cubist.com
As noted in the Mon 23 Mar 2009 press release, Cubist has sued Teva in response to Teva's Abbreviated New Drug Application (ANDA) seeking FDA approval of a generic version of CUBICIN. This patent dispute is critical because, as noted in recent SEC filings, CUBICIN sales account for substantially...
Leading institutions connect with Patrick Joseph Igoe through GLG
GLG Study Groups with Patrick Joseph Igoe(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 766 |
| Medical Device Patent Experts: Lawyers (US) | 77 |
| Biotechnology Patent Experts: Lawyers (US) | 99 |
| Medical Device Experts | 317 |
GLG Live Meetings with Patrick Joseph Igoe(?)
Recent Seminars
-
November 1, 2007 | New York
GLGi: Big Pharma v. Generics - Science Patent Battles